The scleroderma market size has grown strongly in recent years. It will grow from $2.33 billion in 2024 to $2.49 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to advances in diagnosis, immunological research, therapeutic developments, awareness and education, genetic studies.
The scleroderma market size is expected to see strong growth in the next few years. It will grow to $3.25 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to biological therapies, precision medicine, stem cell therapies, genomic and biomarker research, global collaborations. Major trends in the forecast period include digital health solutions, focus on microbiome, patient-centric care, regenerative medicine, health equity and access.
The increasing prevalence of scleroderma is driving the growth of the scleroderma market in the future. Scleroderma is a chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that provides structure to the skin and other tissues. This condition develops due to an unregulated immune response, potentially triggered by various environmental factors. As the number of cases grows, the need for improved diagnosis and treatment becomes clear. Scleroderma therapeutics play a crucial role in managing the disease and alleviating symptoms by regulating the immune response and reducing exposure to environmental risk factors. For instance, in June 2022, Karger Publishers, a Switzerland-based publisher of peer-reviewed journals, reported that there were 19,000 people with scleroderma in the UK and 2.5 million worldwide. Additionally, in August 2024, a research article published by Oxford Academic Press, a UK-based university press affiliated with the University of Oxford, identified 1,588 cases of systemic sclerosis (SSc) among 10.1 million individuals in the CPRD, resulting in the diagnosis of 206 cancers, primarily mucocutaneous (4.5%), lung (2.1%), and breast (1.9%). Therefore, the rising prevalence of scleroderma is driving the scleroderma market.
The exposure to toxins is advancing the growth of the scleroderma market. Exposure to toxins refers to the contact with or ingestion of harmful substances that can negatively impact biological systems. The scleroderma market plays a crucial role in addressing this issue by promoting research, developing targeted therapies, and improving patient care for those affected by scleroderma, a condition with possible environmental and genetic triggers. For instance, in April 2024, data published by the Department for Environment, Food, and Rural Affairs, a UK-based ministerial department, indicated that urban background concentrations increased by 3 percent from 2022, reaching 66.8 µg/m³ in 2023, which is the highest value recorded in the time series. Therefore, exposure to toxins is driving the scleroderma market forward.
The development of novel treatments is a prominent trend gaining traction in the scleroderma market. Leading companies in the market are actively engaged in creating innovative drugs to effectively manage symptoms and maintain their market position. For example, in April 2022, Tyr Pharma Inc., a biotherapeutics manufacturer based in the US, secured regulatory approval from the US Food and Drug Administration for its groundbreaking systemic sclerosis-related interstitial lung disease drug, efzofitimod. This First-in-class immunomodulator targets the neuropilin-2 (NRP2) receptor to downregulate and control the immune response, offering relief from scleroderma symptoms. Moreover, efzofitimod demonstrated efficacy in reducing pro-inflammatory markers in a clinical study involving patients with pulmonary sarcoidosis, further highlighting its potential impact.
Major companies operating in the scleroderma market are emphasizing product launches, including a clinical trial platform, to advance scleroderma treatments and identify promising agents for progression from Phase IIb to Phase III. A clinical trial platform serves as a comprehensive infrastructure facilitating the concurrent assessment of multiple therapies across various clinical trials. In August 2023, The Scleroderma Research Foundation (SRF), a non-profit organization based in the US, introduced CONQUEST, a groundbreaking clinical trial platform. With a global reach spanning 130 centers in 22 countries, CONQUEST employs a master protocol to evaluate multiple therapies simultaneously. This initiative is poised to significantly impact the scleroderma market by accelerating the development and approval of effective therapies through its collaborative and efficient clinical evaluation approach.
In October 2023, Amgen Inc., a U.S.-based biotechnology company, acquired Horizon Therapeutics plc for about $27.8 billion. This acquisition is intended to enhance Amgen's portfolio of first-in-class medicines for rare inflammatory diseases, align with its core strategy of providing innovative treatments, and utilize its biologics research and manufacturing capabilities to improve health outcomes for patients worldwide. Horizon Therapeutics plc is an Ireland-based biotechnology company that focuses on treating scleroderma through Fipaxalparant.
Major companies operating in the scleroderma market include Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, Abbvie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., H.A.C. Pharma.
North America was the largest region in the scleroderma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the scleroderma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Scleroderma is an uncommon autoimmune disease characterized by the chronic and rare abnormal growth of collagen, a protein responsible for forming the structural framework of the skin and other tissues. Various treatments aim to address the excessive production of collagen, either providing cures, halting its overproduction, effectively managing associated symptoms, or reducing the risk of complications linked to scleroderma.
The primary treatments for scleroderma encompass medication, surgery, and other therapeutic approaches. Medication involves the use of substances, typically in the form of drugs or pharmaceuticals, intended to prevent, treat, or manage medical conditions, diseases, or symptoms. Hospitals, pharmaceutical stores, and other healthcare providers commonly administer medications, specifically indicated for treating both systemic scleroderma and localized scleroderma.
The scleroderma market research report is one of a series of new reports that provides scleroderma market statistics, including scleroderma industry global market size, regional shares, competitors with a scleroderma market share, detailed scleroderma market segments, market trends and opportunities, and any further data you may need to thrive in the scleroderma industry. This scleroderma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The scleroderma market consists of revenues earned by entities by providing dilation of blood vessels, immunosuppressants, relieving pain, and reducing infection. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleroderma market also includes the sales of methotrexate, anti-thymocyte globulin, mycophenolate mofetil, and cyclophosphamide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The scleroderma market size is expected to see strong growth in the next few years. It will grow to $3.25 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to biological therapies, precision medicine, stem cell therapies, genomic and biomarker research, global collaborations. Major trends in the forecast period include digital health solutions, focus on microbiome, patient-centric care, regenerative medicine, health equity and access.
The increasing prevalence of scleroderma is driving the growth of the scleroderma market in the future. Scleroderma is a chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that provides structure to the skin and other tissues. This condition develops due to an unregulated immune response, potentially triggered by various environmental factors. As the number of cases grows, the need for improved diagnosis and treatment becomes clear. Scleroderma therapeutics play a crucial role in managing the disease and alleviating symptoms by regulating the immune response and reducing exposure to environmental risk factors. For instance, in June 2022, Karger Publishers, a Switzerland-based publisher of peer-reviewed journals, reported that there were 19,000 people with scleroderma in the UK and 2.5 million worldwide. Additionally, in August 2024, a research article published by Oxford Academic Press, a UK-based university press affiliated with the University of Oxford, identified 1,588 cases of systemic sclerosis (SSc) among 10.1 million individuals in the CPRD, resulting in the diagnosis of 206 cancers, primarily mucocutaneous (4.5%), lung (2.1%), and breast (1.9%). Therefore, the rising prevalence of scleroderma is driving the scleroderma market.
The exposure to toxins is advancing the growth of the scleroderma market. Exposure to toxins refers to the contact with or ingestion of harmful substances that can negatively impact biological systems. The scleroderma market plays a crucial role in addressing this issue by promoting research, developing targeted therapies, and improving patient care for those affected by scleroderma, a condition with possible environmental and genetic triggers. For instance, in April 2024, data published by the Department for Environment, Food, and Rural Affairs, a UK-based ministerial department, indicated that urban background concentrations increased by 3 percent from 2022, reaching 66.8 µg/m³ in 2023, which is the highest value recorded in the time series. Therefore, exposure to toxins is driving the scleroderma market forward.
The development of novel treatments is a prominent trend gaining traction in the scleroderma market. Leading companies in the market are actively engaged in creating innovative drugs to effectively manage symptoms and maintain their market position. For example, in April 2022, Tyr Pharma Inc., a biotherapeutics manufacturer based in the US, secured regulatory approval from the US Food and Drug Administration for its groundbreaking systemic sclerosis-related interstitial lung disease drug, efzofitimod. This First-in-class immunomodulator targets the neuropilin-2 (NRP2) receptor to downregulate and control the immune response, offering relief from scleroderma symptoms. Moreover, efzofitimod demonstrated efficacy in reducing pro-inflammatory markers in a clinical study involving patients with pulmonary sarcoidosis, further highlighting its potential impact.
Major companies operating in the scleroderma market are emphasizing product launches, including a clinical trial platform, to advance scleroderma treatments and identify promising agents for progression from Phase IIb to Phase III. A clinical trial platform serves as a comprehensive infrastructure facilitating the concurrent assessment of multiple therapies across various clinical trials. In August 2023, The Scleroderma Research Foundation (SRF), a non-profit organization based in the US, introduced CONQUEST, a groundbreaking clinical trial platform. With a global reach spanning 130 centers in 22 countries, CONQUEST employs a master protocol to evaluate multiple therapies simultaneously. This initiative is poised to significantly impact the scleroderma market by accelerating the development and approval of effective therapies through its collaborative and efficient clinical evaluation approach.
In October 2023, Amgen Inc., a U.S.-based biotechnology company, acquired Horizon Therapeutics plc for about $27.8 billion. This acquisition is intended to enhance Amgen's portfolio of first-in-class medicines for rare inflammatory diseases, align with its core strategy of providing innovative treatments, and utilize its biologics research and manufacturing capabilities to improve health outcomes for patients worldwide. Horizon Therapeutics plc is an Ireland-based biotechnology company that focuses on treating scleroderma through Fipaxalparant.
Major companies operating in the scleroderma market include Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, Abbvie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., H.A.C. Pharma.
North America was the largest region in the scleroderma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the scleroderma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Scleroderma is an uncommon autoimmune disease characterized by the chronic and rare abnormal growth of collagen, a protein responsible for forming the structural framework of the skin and other tissues. Various treatments aim to address the excessive production of collagen, either providing cures, halting its overproduction, effectively managing associated symptoms, or reducing the risk of complications linked to scleroderma.
The primary treatments for scleroderma encompass medication, surgery, and other therapeutic approaches. Medication involves the use of substances, typically in the form of drugs or pharmaceuticals, intended to prevent, treat, or manage medical conditions, diseases, or symptoms. Hospitals, pharmaceutical stores, and other healthcare providers commonly administer medications, specifically indicated for treating both systemic scleroderma and localized scleroderma.
The scleroderma market research report is one of a series of new reports that provides scleroderma market statistics, including scleroderma industry global market size, regional shares, competitors with a scleroderma market share, detailed scleroderma market segments, market trends and opportunities, and any further data you may need to thrive in the scleroderma industry. This scleroderma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The scleroderma market consists of revenues earned by entities by providing dilation of blood vessels, immunosuppressants, relieving pain, and reducing infection. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleroderma market also includes the sales of methotrexate, anti-thymocyte globulin, mycophenolate mofetil, and cyclophosphamide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Scleroderma Market Characteristics3. Scleroderma Market Trends and Strategies4. Scleroderma Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Scleroderma Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Scleroderma Market34. Recent Developments in the Scleroderma Market
5. Global Scleroderma Growth Analysis and Strategic Analysis Framework
6. Scleroderma Market Segmentation
7. Scleroderma Market Regional and Country Analysis
8. Asia-Pacific Scleroderma Market
9. China Scleroderma Market
10. India Scleroderma Market
11. Japan Scleroderma Market
12. Australia Scleroderma Market
13. Indonesia Scleroderma Market
14. South Korea Scleroderma Market
15. Western Europe Scleroderma Market
16. UK Scleroderma Market
17. Germany Scleroderma Market
18. France Scleroderma Market
19. Italy Scleroderma Market
20. Spain Scleroderma Market
21. Eastern Europe Scleroderma Market
22. Russia Scleroderma Market
23. North America Scleroderma Market
24. USA Scleroderma Market
25. Canada Scleroderma Market
26. South America Scleroderma Market
27. Brazil Scleroderma Market
28. Middle East Scleroderma Market
29. Africa Scleroderma Market
30. Scleroderma Market Competitive Landscape and Company Profiles
31. Scleroderma Market Other Major and Innovative Companies
35. Scleroderma Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Scleroderma Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on scleroderma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for scleroderma? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The scleroderma market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment: Medication; Surgery; Other Treatments2) By Indication: Systemic Scleroderma; Localized Scleroderma
3) By End User: Hospital; Pharmaceutical Stores; Other End Users
Subsegments:
1) By Medication: Immunosuppressants; Antifibrotic Agents; Vasodilators; Corticosteroids; Pain Relievers2) By Surgery: Lung Transplantation; Other Surgical Interventions
3) By Other Treatments: Physical Therapy; Occupational Therapy; Lifestyle Modifications; Alternative Therapies
Key Companies Mentioned: Pfizer Inc.; Johnson and Johnson Inc.; F. Hoffmann-La Roche AG; Abbvie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Johnson And Johnson Inc.
- F. Hoffmann-La Roche AG
- Abbvie Inc.
- Bayer AG
- Novartis AG
- Merck And Co. Inc.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Gilead Sciences Inc.
- Amgen Inc.
- GSK plc
- Teva Pharmaceutical Industries Ltd.
- Astellas Pharma Inc.
- Aspen Pharmacare Holdings Limited
- Boehringer Ingelheim International GmbH
- Principia Biopharma Corp
- aTyr Pharma Inc.
- Cumberland Pharmaceuticals Inc.
- Kadmon Holdings Inc.
- Emerald Health Pharmaceuticals Inc.
- FibroGen Inc.
- Argentis Pharmaceuticals LLC
- Corbus Pharmaceuticals Holdings Inc.
- H.A.C. Pharma
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 2.49 Billion |
| Forecasted Market Value ( USD | $ 3.25 Billion |
| Compound Annual Growth Rate | 6.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 28 |
